Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
| Revenue (TTM) | $37.13M |
| Gross Profit (TTM) | $-91.58M |
| EBITDA | $-150.65M |
| Operating Margin | -919.00% |
| Return on Equity | -72.30% |
| Return on Assets | -24.10% |
| Revenue/Share (TTM) | $0.50 |
| Book Value | $1.13 |
| Price-to-Book | 24.47 |
| Price-to-Sales (TTM) | 49.76 |
| EV/Revenue | 46.11 |
| EV/EBITDA | 0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -90.60% |
| Shares Outstanding | $71.20M |
| Float | $65.81M |
| % Insiders | 1.34% |
| % Institutions | 99.57% |
Volatility is currently expanding
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
Zymeworks Inc. (ZYME) M&A Call Transcript
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows.
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZYME and any ticker you trade — then tracks every position and per-strategy win rate.
